FDA inspection
Janssen Pharmaceuticals, Inc: FDA inspection ending Sep 28, 2020
FDA inspection 1131617 · No Action Indicated (NAI) · Titusville, NJ
Key facts
| Inspection ID | 1131617 |
|---|---|
| Firm | Janssen Pharmaceuticals, Inc |
| FEI number | 2242843 |
| Address | 1125 Trenton Harbourton Rd |
| City | Titusville |
| State | NJ |
| ZIP | 08560 |
| Country | United States |
| Fiscal year | 2020 |
| Inspection end date | Sep 28, 2020 |
| Classification | No Action Indicated (NAI) |
| Project area | Bioresearch Monitoring |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- No Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data